We are a global science-led healthcare company. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare.
Our new business priorities
At an investor event on 26 July, we set out our new business priorities - centred around Innovation, Performance and Trust - which we will implement from 2018 onwards.
Read our new business priorities
We have a significant global presence with commercial operations in more than 150 countries, a network of 87 manufacturing sites, and global R&D hubs in the UK, USA, Belgium, Italy and China.
Our current strategic priorities
The business is focused around the delivery of four strategic priorities which aim to increase growth, reduce risk, improve our long-term financial performance and operate responsibly. These priorities are: grow a balanced global business, deliver more products of value, simplify the operating model and be a responsible business.
Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
Group turnover outside USA and Europe
In 2016, we invested £3.6 billion in our search to develop new medicines, vaccines and consumer products.
Deliver more products of value
We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers.
This is underpinned by a focus on improving productivity and rates of return in R&D.
20 - 30
assets with data expected by 2018
candidate vaccines in early, mid and late stage development
Our range of partners includes academic institutions, public-private partnerships, pharmaceutical and biotechnology companies
Simplify the operating model
As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient.
This frees up resources to reinvest elsewhere in the business, or return to shareholders wherever we see the most attractive returns.
Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
markets operating our new commercial model
in the Access to Medicine Index since launch in 2008
in the Pharmaceutical sector Dow Jones Sustainability Index score for economic, environmental and social performance
GSK's evolving business model - innovation and access
Senior leaders give an insight into some of the ways in which GSK is transforming its business model to be a more responsible business.
Find out more about us
What we do
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
Behind the science
Discover more about what we do, the people behind GSK and how we are working to help change the face of healthcare